Health Herald Grenada: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Herald Grenada.

Press releases published on March 30, 2026

Mar. 30, 2026

Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform

Indeterminate GlobeNewswire

Mar. 30, 2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

Indeterminate GlobeNewswire

Mar. 30, 2026

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Indeterminate GlobeNewswire

Mar. 30, 2026

Data presented at ACC.26 further demonstrate the benefits of iRhythm’s Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform

Indeterminate GlobeNewswire

Mar. 30, 2026

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire

Mar. 30, 2026

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Indeterminate GlobeNewswire

Mar. 30, 2026

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Indeterminate GlobeNewswire

Mar. 30, 2026

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)

Indeterminate GlobeNewswire

Mar. 30, 2026

Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab)

Indeterminate GlobeNewswire

Mar. 30, 2026

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Indeterminate GlobeNewswire

Mar. 30, 2026

Chiesi Global Rare Diseases Receives Positive CHMP Opinion for LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)

Indeterminate GlobeNewswire

Mar. 30, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Mar. 30, 2026

Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting

Indeterminate GlobeNewswire

Mar. 30, 2026

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

Indeterminate GlobeNewswire

Mar. 30, 2026

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Indeterminate GlobeNewswire

Mar. 30, 2026

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

Indeterminate GlobeNewswire

Mar. 30, 2026

electroCore Expands Intellectual Property Portfolio

Indeterminate GlobeNewswire

Mar. 30, 2026

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Indeterminate GlobeNewswire

Mar. 30, 2026

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Indeterminate GlobeNewswire

Mar. 30, 2026

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

Indeterminate GlobeNewswire